Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 222Colorectal Neoplasms 196Rectal Neoplasms 174Stomach Neoplasms 116Pancreatic Neoplasms 100Neoplasm Metastasis 77Colonic Neoplasms 59Neoplasms 50Esophageal Neoplasms 39Triple Negative Breast Neoplasms 38Nasopharyngeal Carcinoma 28Biliary Tract Neoplasms 27Cholangiocarcinoma 22Gallbladder Neoplasms 20Locally Advanced Rectal Cancer 17Carcinoma, Hepatocellular 17Adenocarcinoma 15Gastrointestinal Neoplasms 13Colorectal Cancer Metastatic 13Head and Neck Neoplasms 12Bile Duct Neoplasms 12Adenocarcinoma Of Esophagus 12Esophageal Squamous Cell Carcinoma 11Breast Neoplasms, Male 11Brain Neoplasms 11Liver Neoplasms 10Carcinoma, Renal Cell 10Neuroendocrine Tumors 9Unspecified Adult Solid Tumor, Protocol Specific 8Squamous Cell Carcinoma of Head and Neck 8

Interventions

HMPL-013 1Drug Therapy 1Control Groups 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Unresectable Metastatic Colorectal Cancer × Capecitabine × Clear all
NCT04866108 2022-08-18

A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy

Beijing Friendship Hospital

Phase 2 Unknown
49 enrolled
Gastrointestinal

Unresectable Metastatic Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡